Why the study?
Altered miRNA levels in tissues and circulation can serve as biomarkers for pathological conditions, including structural cardiac diseases.
Population
Patients with dilated, arrhythmogenic, and hypertrophic cardiomyopathy
Design
Review
Authors
Loading...
miRNA biomarkers may aid cardiomyopathy subtyping; leaves open prospective validation before clinical adoption.
MicroRNAs have potential utility as molecular biomarkers in structural cardiomyopathies including dilated, arrhythmogenic, and hypertrophic cardiomyopathy.
Chiti et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: